Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Osteoporosis drug Fosamax linked to heart problem

30.04.2008
Finding from Group Health and University of Washington study

Women who have used Fosamax are nearly twice as likely to develop the most common kind of chronically irregular heartbeat (atrial fibrillation) than are those who have never used it, according to research from Group Health and the University of Washington published in the April 28 Archives of Internal Medicine.

Merck markets Fosamax, the most widely used drug treatment for the bone-thinning disease osteoporosis, explained study leader Susan Heckbert, MD, PhD, MPH, a professor of epidemiology and scientific investigator in the Cardiovascular Health Research Unit at the University of Washington. The Food and Drug Administration (FDA) approved the first generic versions (called alendronate) in February.

“We studied more than 700 female Group Health patients whose atrial fibrillation was first detected during a three-year period,” said Dr. Heckbert. She and her colleagues compared those women to over 900 randomly selected female Group Health members matched on age and high blood pressure to serve as controls.

“Having ever used alendronate was associated with an 86 percent higher risk of newly detected atrial fibrillation compared with never having used the drug,” said Dr. Heckbert, who is also an affiliate investigator at the Group Health Center for Health Studies.

Osteoporosis mostly affects older women and can set the stage for fractures that can impair the quality of their lives, said Dr. Heckbert. “Careful judgment is required to weigh the risks and benefits of any medication for any individual patient,” she added. “For most women at high risk of fracture, alendronate’s benefit of reducing fractures will outweigh the risk of atrial fibrillation.”

However, said Dr. Heckbert, “women who are at high risk of fractures but also have risk factors for atrial fibrillation—such as heart failure, diabetes, or coronary disease—might want to discuss alternatives to alendronate with their health care providers.” Other medications that can lower the risk of fractures include estrogen, she said. But the Women’s Health Initiative, on which she has also served as an investigator, showed other heart risks from hormone therapy combining estrogen with progesterone.

The National Heart, Lung, and Blood Institute funds Dr. Heckbert’s Atrial Fibrillation Study, which collects data on all Group Health patients as they are first diagnosed with atrial fibrillation. The study aims to find new factors that raise the risk of developing this quivering of the heart’s upper chambers (atria).

About one in 100 people—and nearly nine in 100 people over age 80—have atrial fibrillation, said Dr. Heckbert. In many cases, atrial fibrillation has no symptoms, and it isn’t necessarily life threatening. But it can cause palpitations, fainting, fatigue, or congestive heart failure.

Atrial fibrillation can also make blood pool—and sometimes clot—in the atria, said Dr. Heckbert. When parts of clots break off and leave the atria, they can lead to embolic strokes, as happens in over 70,000 Americans a year. That’s why atrial fibrillation is often treated with the anticoagulant warfarin. Other results from her study have suggested that maintaining a healthy body weight may help protect people from atrial fibrillation.

“This study will help medical teams better inform their patients about the risks associated with Fosamax, helping us make the best treatment decisions for managing osteoporosis,” commented Christine Himes Fordyce, MD, a Group Health family practitioner. “Now with this increased understanding of potential irregular heartbeats, both physicians and their patients should be alert to any problems, report them immediately, and treat them appropriately.”

Rebecca Hughes | EurekAlert!
Further information:
http://www.ghc.org

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Quantum thermometer or optical refrigerator?

23.06.2017 | Physics and Astronomy

A 100-year-old physics problem has been solved at EPFL

23.06.2017 | Physics and Astronomy

Equipping form with function

23.06.2017 | Information Technology

VideoLinks
B2B-VideoLinks
More VideoLinks >>>